Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 4: 961 - 971

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.04.016

Original Articles

Efficacy and safety of Heshu Xiaoji pills (和枢消积丸) combined with standard treatment strategy in hepatitis B virus-related hepatocellular carcinoma: a single-center, open-label, prospective controlled, real-world cohort study

  • ZHU Xiaoning ,
  • YIN Yue ,
  • KONG Yuan ,
  • PENG Mengyun ,
  • PENG Zhaoxuan ,
  • ZHENG Ding ,
  • WANG Xiaodong ,
  • HAN Yunwei ,
  • LI Bo ,
  • LIU Jurong ,
  • WANG Encheng ,
  • TIAN Zhen ,
  • PENG Qinghua ,
  • JIANG Yuanyuan ,
  • MI Shaoping ,
  • LIU Yong ,
  • PU Qingrong ,
  • GUO Yongcan ,
  • HE Qizhou ,
  • CHENG Chunxia ,
  • LI Linghua ,
  • JIA Hong ,
  • WANG Jing
Expand
  • 1 Department of Hepatobiliary Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China; Sichuan Clinical Research Center for Traditional Chinese Medicine of Liver Diseases, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
    2 School of Public Health, Center for Evidence-Based Medicine, Southwest Medical University, Luzhou 646000, China
    3 Sichuan Clinical Research Center for Traditional Chinese Medicine of Liver Diseases, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China; Department of Oncology, the Affiliated Hospital, Southwest Medical University, Luzhou 646000, China
    4 Department of Hepatobiliary Surgery, the Affiliated Hospital, Southwest Medical University, Luzhou 646000, China
    5 Department of Medical Imaging, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
    6 Institute of Pharmacy, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
    7 Department of Laboratory Medicine, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
    8 Department of Ultrasound, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
    9 Department of Electrocardiography, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China
ZHU Xiaoning and YIN Yue are co-first authors and contributed equally to this work

Received date: 2025-06-18

  Accepted date: 2025-11-18

  Online published: 2026-08-08

Supported by

Sichuan Science and Technology Program-funded Project: Evidence-based Research on Precision Treatment Strategies Using Traditional Chinese Medicine for Primary Liver Cancer(2024YFFK0086);Program of Southwest Medical University-funded Project: Mechanistic Study of Heshu Xiaoji Pills Targeting MicroRNAs to Regulate Cancer Stem Cells and Reduce Hepatocellular Carcinoma Recurrence(2023ZYYJ08);Natural Science Foundation of Sichuan Province-funded Project: Basic and Clinical Research on the Prevention and Treatment of Primary Liver Cancer Based on the Academic Thought of Professor Sun Tongjiao, a Nationally Renowned Traditional Chinese Medicine Practitioner(2022YFS0619);National Traditional Chinese Medicine Clinical Research Base Construction Unit of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou Science and Technology Innovation Team, and the Science and Technology Innovation Team of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University

Fold

Abstract

OBJECTIVE: To evaluate the effectiveness and safety of Heshu Xiaoji pills (HSXJ, 和枢消积丸) as an adjunct to standard treatment in patients with hepatitis B virus-related hepatocellular carcinoma.

METHODS: Overall, 201 patients enrolled between May 2020 and February 2022 received either HSXJ plus standard treatment (TCM group, n = 136) or standard treatment alone (Control group, n = 65). Follow-up continued until February 2023. Propensity score matching (PSM) (2∶1) was used to adjust for baseline differences, yielding 61 TCM and 39 control patients. Overall survival (OS), progression-free survival (PFS), and safety were compared using multivariate Cox proportional hazard regression.

RESULTS: Before PSM, OS and PFS were significantly longer in the TCM group than in the Control group (OS: 609 vs 500 d; PFS: 609 vs 507 d). After PSM, PFS remained significantly longer (551 vs 449.5 d), but OS differences were not statistically significant. Adverse events were comparable between groups. Subgroup analysis identified patients with cirrhosis, prior resection or local therapy, Child-Pugh A stage, HBV-DNA ≥ 2000 IU/mL, and alpha-fetoprotein ≤ 200 ng/mL as the most responsive to this TCM therapy.

CONCLUSIONS: HSXJ combined with standard treatment strategy significantly improved PFS in patients with HBV-related HCC without added safety risks.

Key words： carcinoma, hepatocellular; chemotherapy, adjuvant; real-world cohort study; Heshu Xiaoji pills

Cite this article

ZHU Xiaoning , YIN Yue , KONG Yuan , PENG Mengyun , PENG Zhaoxuan , ZHENG Ding , WANG Xiaodong , HAN Yunwei , LI Bo , LIU Jurong , WANG Encheng , TIAN Zhen , PENG Qinghua , JIANG Yuanyuan , MI Shaoping , LIU Yong , PU Qingrong , GUO Yongcan , HE Qizhou , CHENG Chunxia , LI Linghua , JIA Hong , WANG Jing . Efficacy and safety of Heshu Xiaoji pills (和枢消积丸) combined with standard treatment strategy in hepatitis B virus-related hepatocellular carcinoma: a single-center, open-label, prospective controlled, real-world cohort study[J]. Journal of Traditional Chinese Medicine, 2026 , 46(4) : 961 -971 . DOI: 10.19852/j.cnki.jtcm.2026.04.016

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
2. Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health 2023; 8: e943-55.
3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77: 1598-606.
4. Calderon-Martinez E, Landazuri-Navas S, Vilchez E, et al. Prognostic scores and survival rates by etiology of hepatocellular carcinoma: a review. J Clin Med Res 2023; 15: 200-7.
5. Tsuge M, Kawaoka T, Oka S. Factors for the recurrence of hepatocellular carcinoma after hepatic resection. J Gastroenterol 2023; 58: 292-3.
6. Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol 2024; 10: 395-404.
7. Llovet JM, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol 2024; 21: 294-311.
8. Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1835-47.
9. Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg 2019; 154: 209-17.
10. Liao X, Bu Y, Jia Q. Traditional Chinese Medicine as supportive care for the management of liver cancer: past, present, and future. Genes Dis 2020; 7: 370-9.
11. Liu X, Li M, Wang X, et al. Effects of adjuvant Traditional Chinese Medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine 2019; 62: 152930.
12. Li Y, Li Y, Zhang J, et al. Current perspective of Traditional Chinese Medicines and active ingredients in the therapy of hepatocellular carcinoma. J Hepatocell Carcinoma 2022; 9: 41-56.
13. Chen X, Wang J, Zhu X, Zhang Y, Peng Z. The effect of Heshu Xiaoji prescription on tumor suppression and tumor tissue VEGF and PDGF proteins in H22 tumor-bearing mice. Zhong Xi Yi Jie He Gan Bing Za Zhi 2024; 34: 336-40.
14. Benson AB, D’Angelica MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 2.2019: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2019; 17: 302-10.
15. Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer 2020; 9: 682-720.
16. Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhong Hua Gan Zang Bing Za Zhi 2019; 27: 938-61.
17. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 5.0. Bethesda (MD): National Cancer Institute; 2017: 1-155.
18. Kane LT, Fang T, Galetta MS, et al. Propensity score matching: a statistical method. Clin Spine Surg 2020; 33: 120-2.
19. Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018; 67: 2006-16.
20. Cheng Y, Ni S, Chen Y, Ling Q, Chen J. Erzhu Qinggan Jiedu recipe improves the clinical outcome of hepatocellular cancer after surgical resection: a case-control retrospective study. Intern Med J 2021; 51: 853-60.
21. Wang J, Luo J, Yin X, et al. Jiedu granule combined with transcatheter arterial chemoembolization and Gamma knife radiosurgery in treating hepatocellular carcinoma with portal vein tumor thrombus. Biomed Res Int 2019; 2019: 4696843.
22. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-54.
23. Cabibbo G, Celsa C, Rimassa L, et al. Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice. J Hepatol 2024; 80: 957-66.
24. Xu L, Wang S, Zhuang L, et al. Jianpi Liqi decoction alleviated postembolization syndrome following transcatheter arterial chemoembolization for hepatocellular carcinoma: a randomized, double-blind, placebo-controlled trial. Integr Cancer Ther 2016; 15: 349-57.
25. Haber PK, Puigvehí M, Castet F, et al. Evidence-based management of hepatocellular carcinoma: systematic review and Meta-analysis of randomized controlled trials (2002-2020). Gastroenterology 2021; 161: 879-98.
26. Raghav A, Jeong GB. Phase I-IV drug trials on hepatocellular carcinoma in Asian populations: a systematic review of ten years of studies. Int J Mol Sci 2024; 25: 9286.
27. Wang K, Xiang YJ, Yu HM, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med 2024; 30: 708-15.
Options
Outlines

/

〈 〉